Radiotherapy versus laser microsurgery in the treatment of early glottic cancer

Glottic squamous cell carcinoma (SCC) in stages I or II can be treated by transoral CO 2 laser microsurgery (TLM) or exclusive radiotherapy (RT). To compare the oncological results of patients treated with TLM, to those treated with RT, in a tertiary hospital. Data from patients diagnosed with glott...

Full description

Saved in:
Bibliographic Details
Published inActa oto-laryngologica Vol. 140; no. 11; pp. 954 - 958
Main Authors Lois-Ortega, Yolanda, García-Curdi, Fernando, Sebastián-Cortés, José Miguel, De Miguel-García, Félix, Vallés-Varela, Héctor, Muniesa-del Campo, Ana
Format Journal Article
LanguageEnglish
Published Taylor & Francis 01.11.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Glottic squamous cell carcinoma (SCC) in stages I or II can be treated by transoral CO 2 laser microsurgery (TLM) or exclusive radiotherapy (RT). To compare the oncological results of patients treated with TLM, to those treated with RT, in a tertiary hospital. Data from patients diagnosed with glottic SCC in stages I and II between 2004 and 2018 were analyzed. Response to treatment was studied in terms of recurrence, local control and laryngeal preservation. Of 164 patients, 63.41% received treatment with TLM and 36.58% with RT. 26.21% presented a recurrence or progression of the tumor. Both treatments obtained good local control rates (84.15% in the case of TLM and 89.6% in the case of RT) and no significant association was found between tumor recurrence and type of treatment, nor with the involvement of the anterior commissure. However, treatment with RT obtained worse laryngeal preservation rate compared to TLM (81.6% and 100% respectively) (p < .001LR). Conclusions and significance: Both treatments obtained good oncological results. There were no significant differences regarding local control. However, TLM obtained a better laryngeal preservation rate. The involvement of the anterior commissure was not a poor prognosis factor for tumor recurrence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0001-6489
1651-2251
DOI:10.1080/00016489.2020.1788723